Skip to main content
. Author manuscript; available in PMC: 2020 Jan 15.
Published in final edited form as: Circulation. 2019 Jan 15;139(3):313–321. doi: 10.1161/CIRCULATIONAHA.118.038261

TABLE 3.

Serious Adverse Events (SAEs) Within 90 Days of Treatment. The first column organizes CTCAE v4.0 adverse events by system and then further divides into specific adverse events. The first row indicates the grade as well as the attribution. No grade 4 events were recorded, and are thus not tabulated. Protocol-specific SAEs (SAEs that were possibly, probably, or definitely relative to study treatment) are bolded. CTCAE v4.0 = Common Terminology Criteria for Adverse Events version 4.0.

CTCAE v4.0 System/Toxicity Grade 3 Grade 5
Unrelated Unlikely Possible Probable Unlikely
Cardiac disorders
 Heart Failure 1
 Pericarditis 1
Gastrointestinal disorders
 Diarrhea 1
 Nausea 1
General disorders and administration site conditions
 Other - Accident 1
Immune system disorders
 Allergic Reaction 1
Investigations
 Alanine Aminotransferase increased 1
 Aspartate Aminotransferase increased 1
Respiratory, thoracic and mediastinal disorders
 Other – Influenza 1
Vascular disorders
 Flushing 1